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Background: The master transactivator CIITA is essential to the regulation of Major Histocompatibility Complex (MHC)
class II genes and an effective immune response. CIITA is known to modulate a small number of non-MHC genes
involved in antigen presentation such as CD74 and B2M but its broader genome-wide function and relationship
with underlying genetic diversity has not been resolved.
Results: We report the first genome-wide ChIP-seq map for CIITA and complement this by mapping inter-individual
variation in CIITA expression as a quantitative trait. We analyse CIITA recruitment for pathophysiologically relevant
primary human B cells and monocytes, resting and treated with interferon-gamma, in the context of the epigenomic
regulatory landscape and DNA-binding proteins associated with the CIITA enhanceosome including RFX, CREB1/ATF1
and NFY. We confirm recruitment to proximal promoter sequences in MHC class II genes and more distally involving
the canonical CIITA enhanceosome. Overall, we map 843 CIITA binding intervals involving 442 genes and find 95% of
intervals are located outside the MHC and 60% not associated with RFX5 binding. Binding intervals are enriched for
genes involved in immune function and infectious disease with novel loci including major histone gene clusters. We
resolve differentially expressed genes associated in trans with a CIITA intronic sequence variant, integrate with CIITA
recruitment and show how this is mediated by allele-specific recruitment of NF-kB.
Conclusions: Our results indicate a broader role for CIITA beyond the MHC involving immune-related genes.
We provide new insights into allele-specific regulation of CIITA informative for understanding gene function
and disease.Background
The transcriptional regulation of the CIITA gene (also
referred to as C2TA or MHC2TA) on chromosome
16p13, and the impact of genetic variation involving this
gene for disease, has been extensively characterised follow-
ing the identification of rare loss-of-function mutations in
CIITA resulting in the bare lymphocyte syndrome and se-
vere immunodeficiency due to lack of expression of Major
Histocompatibility Complex (MHC) class II genes [1].
CIITA was found to encode a critical non-DNA binding
factor, the master MHC class II transactivator, which is* Correspondence: julian@well.ox.ac.uk
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unless otherwise stated.recruited to the class II enhancer complex and plays a crit-
ical role in expression of MHC class II genes and, as a
result, in the adaptive immune response through antigen
presentation to CD4+ T cells [2].
CIITA is expressed in a variety of antigen presenting
cells both constitutively and following induction, notably
after interferon-gamma (IFNγ), with transcriptional regu-
lation of CIITA found to be complex and highly context
specific. This includes the occurrence of four different
promoters, each with a unique first exon, conferring con-
siderable cellular specificity with, for example, the CIITA
class III promoter important for constitutive expression in
B cells while the class IV promoter is critical to inducible
expression [2-5]. A number of enhancer elements have
also been identified, including at least five elements over a
110 kb region spanning the gene [6].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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complex mechanisms including chromatin remodelling,
transcriptional initiation and elongation [2]. However it
does not directly bind DNA. Rather, it is recruited to the
proximal promoter regions of the classical MHC class II
genes (HLA-DP, HLA-DR and HLA-DQ), and to HLA-
DM, HLA-DO and the CD74 gene (encoding the molecu-
lar chaperone invariant chain which associates with the
MHC class II complex) through protein-protein interac-
tions with other components of the MHC class II enhan-
ceosome. These include the regulatory factor X complex
(RFX5, RFXANK and RFXAP), the cAMP responsive
element binding protein (CREB1) and activating transcrip-
tion factor 1 (ATF1), and nuclear factor Y (NFYA/B/C
subunits) which bind DNA through the SXY module, a
highly constrained series of sequences (S-X-X2-Y boxes)
spanning 59 to 68 bp and typically located within 300 bp
of the site of transcriptional initiation [2,7,8]. In addition,
more distal SXY modules with enhancer activity have been
identified within the MHC class II region [9]. SXY mod-
ules are also found in the MHC class I region where
CIITA is recruited but has an ancillary role, the major
trans-activator here being NLRC5 [10]. In addition to
CD74 and B2M, a small number of non-MHC target
genes for CIITA have been identified following chro-
matin immunoprecipitation (ChIP) for CIITA analysed
using promoter arrays [8] and differential gene ex-
pression in cell lines deficient in CIITA [11] including
RFX5, TPP1, RAB4B, PSMD3 and MYBPC2 which were
found to depend on RFX recruitment to a promoter X-box
sequence.
Genome-wide functional genomic approaches provide
new opportunities to systematically define such regula-
tory elements and the impact of genetic variation. Here
we describe the first ChIP-seq derived genome-wide
map for CIITA occupancy, set in the context of comple-
mentary data for other DNA-binding protein members
of the CIITA enhanceosome and regulatory features of
the epigenomic landscape. We demonstrate how this
can be integrated with data mapping the genetic deter-
minants of inter-individual variation in CIITA expres-
sion, resolving associated target genes for CIITA both
within the MHC and in the larger genomic space outside
the MHC. We show how a specific intronic regulatory
variant of CIITA is associated in trans with a network
of target genes and modulates allele-specific recruitment
of NF-KB.
Results
A genome-wide map of CIITA recruitment in human B
cells and monocytes
In order to generate a high-resolution genome-wide map
of CIITA recruitment, we performed ChIP for CIITA
followed by high throughput sequencing (ChIP-seq) inprimary human B cells and monocytes. Published work
to date suggests that CIITA binding is associated with
RFX binding to an X box sequence and our experimen-
tal design included generating ChIP-seq data for CIITA
and RFX5 using chromatin prepared from the same
cells. We analysed CD19+ B cells, which show high con-
stitutive levels of MHC class II expression, together with
CD14+ monocytes either resting or treated with IFNγ as
an inducible paradigm for MHC class II expression, as
this cytokine is known to significantly upregulate gene
expression [12].
ChIP-seq peaks for CIITA and RFX5 were scored
using the model-based analysis of ChIP (MACS) after
mapping to the reference human genome haplotype se-
quence for the MHC region (chr6: 29,580,000-33,100,000).
We defined a set of 1,010 binding intervals (BIs) genome-
wide for CIITA and RFX5 across 12 samples derived from
highly purified CD19+ B cells and CD14+ monocyte pop-
ulations from two different healthy individuals (Figure 1A
and Additional file 1: Table S1). Within a given cell type
or condition, BIs were defined as CIITA and/or RFX5
enriched ChIP-seq peaks present in both individuals.
When we performed an analysis of CIITA and RFX5 affin-
ities (differences in read densities) across the BIs, this par-
titioned the binding profiles for B cells and monocytes
into two distinct groupings consistent with cell type
(Additional file 2: Figure S1A). For CIITA, we identified
329 BIs in B cells, 81 in resting monocytes and 591 in
monocytes treated with IFNγ. Specific known and novel
CIITA BIs were validated by ChIP for a third individual
using a different CIITA antibody (Additional file 2:
Figure S2). We integrated all CIITA and RFX5 BIs across
the 12 ChIP-seq datasets (Additional file 1: Table S1)
with DNase I hypersensitivity site (DHS) maps for pri-
mary B cells and monocytes [13]. This revealed that
genome-wide, 95% of CIITA BIs in B cells and 79% in
naïve monocytes are co-incident with a DHS (Additional
file 1: Table S1). We investigated the overall relationship
with components of the canonical CIITA enhanceosome
RFX5, CREB1, ATF1, NFYA and -YB for CIITA BIs. The
majority of BIs, 81% and 98% for B cells and naïve mono-
cytes, respectively, have data coincidence scores (DCS)
greater than 4 (Additional file 1: Table S1 & Additional
file 2: Figure S1B) suggesting that genome-wide, CIITA
occupancy involves sites of accessible chromatin and that
other constituents of the canonical enhanceosome may
be relevant to recruitment.
We proceeded to characterise further the relationship
of CIITA and RFX5, defining instances where CIITA BIs
are co-incident with RFX5 binding as CIITA Enhanceo-
some marks (CE-marks) (Figure 1A and B). In primary
human CD19+ B cells, 329 CIITA and 318 RFX5 BIs
were mapped genome-wide (Additional file 1: Table S1)
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Figure 1 CIITA and RFX5 binding in B cells, naïve and IFNγ treated monocytes. (A) Numbers of CIITA and RFX5 BIs identified as occurring
alone or overlapping. Counts shown genome-wide, within the MHC or excluding the MHC (MHC region defined as chr6: 29,580,000-33,100,000).
(B) Chromosomal location of CE-marks and of non-overlapping CIITA and RFX5 BIs.
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region (chr6: 32,400,000-33,100,000), we found all CIITA
BIs were CE-marks. For primary CD14+ monocytes in a
naïve state, there were 81 CIITA and 105 RFX5 BIs of
which 81% overlap to form CE marks (Figure 1A) whilewithin the MHC Class II region, there were 17 CIITA BIs
that, as observed with B cells, were all CE marks. When
monocytes were treated with IFNγ, we observed 591 CIITA
BIs (a 7.3-fold increase compared to the naïve state) with
28% of CIITA BIs being co-incident with RFX5 and
Wong et al. Genome Biology 2014, 15:494 Page 4 of 15
http://genomebiology.com/2014/15/10/494forming CE marks. Within the MHC Class II region the
proportion of CE marks increased to 78% and of these,
7/31 were stimulus specific. In contrast, all CIITA BIs
within the MHC Class II region of naïve monocytes were
also present in treated cells. Similarly, outside of the MHC
we observed a lower proportion of CIITA binding in naïve
monocytes as compared with induced (Figure 1A). We ob-
served that some CE marks were identified across all cell
types and conditions both within and outside of the MHC
region. Overall, we find that for B cells and resting mono-
cytes all CIITA BIs within the MHC class II region were
CE marks while only 78% were CE marks following IFNγ
treatment of monocytes (Figure 1A). We found that out-
side the MHC region, in B cells and naïve monocytes 66%
and 77%, respectively, of CIITA BIs were CE marks while
after IFNγ treatment only 25% of CIITA BIs in monocytes
were identified as CE marks.
We next considered the relationship of CIITA BIs with
genes and gene networks. We defined a potential func-
tional relationship with a gene when the distance of a
CIITA BI from the transcriptional start site (TSS) of a
gene was <10 kb (5′ or 3′). Following this definition, we
found that 635 of 843 CIITA BIs (75%) were associated
with a gene (Figure 2A), with a total of 442 genes identi-
fied (Additional file 1: Table S1). CIITA BIs in B cells,
naïve monocytes and monocytes treated with IFNγ
showed association with 242, 40 and 271 genes, respect-
ively (Additional file 1: Table S1). Across all cell types
and conditions, a single BI was found within 2 kb of the
TSS for 75% to 94% of these genes. For a further 3% to
16% of these genes a single, more distal BI within 10 kb
of the TSS was present. Finally, for the remaining 5% to
9% of these genes there was association with both prox-
imal and more distal BIs.
We identified networks enriched for genes associated
with a CIITA BI for genome-wide data using DAVID
(the database for annotation, visualization and integrated
discovery) bioinformatics resources [14,15] and Ingenuity
Pathway Analysis tools. The enriched gene networks re-
vealed biological themes related to immunity and inflam-
mation, with antigen presentation the most significantly
enriched pathway on global analysis of all CIITA BI
associated genes (P = 4.7 × 10-19) and when CIITA BIs
identified in each of the specific cell types were analysed
(Additional file 1: Table S1). Signalling involving OX40, a
member of the TNFR superfamily important in T cell ac-
tivation, was also significantly enriched on analysis of all
CIITA BI genes (P = 1.8 × 10-18) and for individual cell
types. In terms of disease, we found that autoimmune
disease phenotypes were significantly enriched across dif-
ferent cell types in the CIITA BI associated genes. In
B cells, RFX5 was the most significant predicted up-
stream transcriptional regulator (P = 1.4 × 10-9) together
with NLRC5 (P = 3.6 × 10-8), SRF (P = 3.8 × 10-6) andCIITA (P = 4.4 × 10-5) while in naïve monocytes RFX5
(P = 4.6 × 10-9) and CIITA (2 × 10-7) were most significant
(Additional file 1: Table S1). In induced monocytes, a more
complex picture was seen with STAT1 (P = 9.3 × 10-12),
NFkB complex (P = 1.5 × 10-10) and IRF1 (P = 1.1 × 10-9)
identified as upstream regulators together with RFX5
(P = 3.3 × 10-9).
We proceeded to examine for possible enrichment of
genes associated with a CIITA BI among genes that are
differentially expressed in monocytes after IFNγ treat-
ment [16]. We found significant enrichments of such
genes, with highest enrichment when a CE mark was
present but there was also an enrichment of genes associ-
ated with a CIITA BI where RFX5 was absent (Figure 2B).
There was a similar enrichment observed when genes
associated with CIITA BIs (combined set of CE marks
and CIITA BIs without RFX5) were segregated into
known CIITA targets (Additional file 1: Table S1) and
novel CIITA targets identified in this study (Figure 2C).
At the same time, we also observed that there were other
instances whereby differential gene expression between
naïve and treated monocytes we previously defined in a
large cohort [16] were not associated with a change in
CIITA occupancy (Additional file 2: Figure S3).
Resolving proximal and distal sites of CIITA recruitment in
the MHC class II region
CIITA is known to be recruited to the enhanceosome
complex at proximal promoter SXY sequences of clas-
sical MHC class II genes with a small number of more
distal enhancer elements recruiting CIITA identified
based on sequence homology with the SXY module [9].
Within the MHC class II region we identified a total of
30 CIITA BIs across freshly isolated B cells and mono-
cytes. The majority (73%) of these CIITA BIs were lo-
cated within 10 kb of the TSS including classical genes
such as HLA-DP, HLA-DR and HLA-DQ (Figure 3). Fur-
thermore, for all of these genes there was a CIITA BI lo-
cated proximally within 2 kb of the promoter (Additional
file 1: Table S1). We observed that IFNγ treatment in
monocytes resulted in nine additional CIITA BIs not
present in naïve cells (8 proximal; 1 distal) that were asso-
ciated with BRD2, PSMB8, HLA-DRA, -DQA, -DQB
and -DOA (Figure 3).
We resolved proximal and distal CIITA recruitment
within the MHC class II region as illustrated by the fol-
lowing examples. For HLA-DRA, we found evidence of a
proximal and a more distal CIITA BI (Figure 4A) with
the latter corresponding to a known site for CIITA occu-
pancy [9]. In this instance, both CIITA BIs were associ-
ated with RFX5 binding (CE marks), located within
transcriptionally accessible regions (DNaseI DHS) and
associated with other features of the MHC enhanceo-
some including binding by CREB1, ATF1, NFYA and -YB.
Figure 2 CIITA BIs in relation to gene location, CIITA module and gene function. (A) Distribution of CIITA BIs showing relative distances
from the TSS of genes. (B) Enrichment of genes that were differentially expressed in treated monocytes within two groupings of CIITA target
genes, one associated with CE marks (CIITA BIs overlapping RFX5) and the other CIITA BIs without RFX5. The empirical cumulative distribution
functions (eCDFs) for each grouping is shown with a 95% confidence interval. A group of CIITA targets containing a larger than expected number
of differentially expressed genes will produce an eCDF that lies above the line corresponding to absence of enrichment. (C) Enrichment for all
CIITA BIs (overlapping and non-overlapping with RFX5) associated with known and novel CIITA target genes in treated monocytes. (D) Box plot
showing averaged rate of MATCH-PWM binding site scores for a CIITA module of RFX5, CREB and NF-Y motifs (co-factors of the classical CIITA
enhanceosome) in promoters of known CIITA target genes and those identified in this study (denoted as novel targets where CIITA BIs localised
within 10 kb 5′ of the TSS). For known and novel target genes, 150 bp intervals centred on CIITA peak summits were analysed. A control
set comprised of 1,000 randomly selected segments is included for comparison. Distributions of the three sets were compared using
Mann-Whitney-Wilcoxon test, showing that these are significantly different, between the control set and known CIITA targets (P = 2.2 × 10-16) or
novel targets (P = 1.5 × 10-11), and between known and novel targets (P = 2.7 × 10-7).
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Figure 3 Location of CIITA BIs and CE marks within the MHC Class II region (chr6: 32,400,000-33,100,000). Numbers of CIITA BIs inclusive
of CE marks are shown in parentheses.
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regions of HLA-DRB1 and HLA-DQA1 and identified a
further four CIITA BIs between these genes (Additional
file 2: Figure S4). These included a CIITA BI localising
to an isoform specific promoter for HLA-DQA1 (chr6:
32590730-32591333); a CIITA BI localising to the XL9
intergenic regulatory element previously reported to bind
CIITA while also recruiting CTCF to enable chromatin
looping and modulation of HLA-DRB1 and HLA-DQA1
gene expression (chr6: 32595564-32596093) [17]; a previ-
ously reported CIITA BI (chr6: 32577249-32578269) [9];
and a novel CIITA BI (chr6: 32571777-32572798) that has
not been previously described. All were CE marks in at
least a single cell type and condition.
We also identified a distal CIITA BI in an intergenic
region 50.9 kb 5′ of HLA-DQA2 (chr6: 32657986-
32658366). This site has previously been reported as a
target of CIITA and RFX5 [9] and we found evidence of a
CE mark in B cells with inducibility in monocytes treated
with IFNγ. Finally, we resolved in the region spanning
HLA-DOA and HLA-DPA1 that there were two proximal
promoter CIITA BIs and a further two more distal CIITA
BIs (chr6: 32986547-32987178 and chr6: 32996961-
32997920), both of which were also CE marks. The
former is novel while the latter has been reported to be a
target of CIITA and RFX5 [9].
Within the MHC class I region (chr6: 29640000-
31325000), where CIITA plays an ancillary role [10],
we identified 11 CIITA BIs of which 10 are CE marks(Additional file 1: Table S1). These included the proximal
promoter regions of classical class I genes including HLA-
A, HLA-B, HLA-C, HLA-E and HLA-F. In addition we
found evidence of CE marks at TRIM26 in B cells and
monocytes, consistent with earlier reports [8], and novel
recruitment at the proximal promoter of PPP1R10 in B
cells (Additional file 2: Figure S5). PPP1R10 encodes the
protein phosphatase I regulator PNUTS, recently shown to
play a key role in DNA damage repair [18].
Non-MHC CIITA recruitment
We observed that of 843 CIITA BIs identified across B
cells and monocytes, the majority were located outside
of the MHC (90% of CIITA BIs in B cells, 79% in naïve
monocytes, 93% in treated monocytes). For these CIITA
BIs, 40% were associated with RFX5 binding and classi-
fied as CE marks. As observed within the MHC, the ma-
jority of CIITA BIs associated with a gene (<10 kb from
TSS) were similarly localised in terms of proximity to
the TSS (70% are within 2 kb of the TSS compared to
82% within the MHC class II region; Figure 2A and
Additional file 2: Figure S6) and within transcriptionally
accessible regions of the genome (Additional file 2:
Figure S1B and Additional file 1: Table S1).
Our global analysis of genes associated with CIITA BIs
highlighted gene networks related to immunity and in-
flammation (Additional file 1: Table S1). Considering all
CIITA BIs we identified outside the MHC, we found
greater diversity in the associated pathways with EIF2
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Figure 4 CIITA binding intervals for a classical gene within the MHC class II region and in a histone cluster 1. (A) Identification of two CIITA BIs,
one proximal and other distal to the TSS of HLA-DRA. Both are CE marks and binding is associated with other constituents of the CIITA Enhanceosome
(NFYA/ -YB; ATF1 and CREB1) and are positioned within DNase I hypersensitive sites. (B) Multiple CIITA BIs within a major histone cluster at chr 6p21.3.
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and JAK/STAT signalling were also enriched. Cell prolifera-
tion (P = 7.3 × 10-12) and RNA expression (P = 4 × 10-11)
were significantly enriched in terms of biological process.
Striking enrichment was also seen for viral infection
(P = 4.5 × 10-11) involving 82 genes together with a number
of disease phenotypes involving arthritis (Additional file 1:
Table S1).
CIITA binding has been previously reported for re-
gions outside the MHC, notably CD74 and B2M which
both encode key components found in MHC class II
and class I molecules, respectively [8,19]. Our ChIP-seq
maps resolved a CE mark located proximally to the TSS
of CD74 on chromosome 5 (Additional file 1: Table S1
and Additional file 2: Figure S7). CIITA occupancy at
this location has been previously described by Krawczyk
and co-workers [8]. There was also a CE-mark located at
the proximal B2M promoter (Additional file 1: Table S1
and Additional file 2: Figure S8). Our datasets also con-
firmed previously reported CIITA targets [8] with CIITA
BIs including CE marks identified at RFX5, TPP1,
RAB4B, ZNF672, HAUS5 and MYBPC2/SPIB. These re-
ported targets had lower P values for the confidence of
calling peak summits (Additional file 2: Figure S9).
In both B cells and treated monocytes, we observed
the presence of multiple histone genes within the
enriched gene networks (Additional file 1: Table S1).
These included the histone H3.3B gene H3F3B for which
a CE mark can be found at the proximal promoter
(chr17: 73775313-73776112). Within the large histone
gene cluster at 6p21.3-6p22, we identified a further 11
CIITA BIs encompassing four CE marks corresponding
to proximal promoter regions of HIST1 genes includ-
ing HIST1H1C, HIST1H2BC, HIST1H2BD, HIST1H4D,
HIST1H2AD, HIST1H4E, HIST1H2BG, HIST1H2BI and
HIST1H4H (Figure 4B). We found another grouping of
CIITA BIs including CE marks at a second major his-
tone gene cluster with HIST2H2AB and HIST2H2BE at
chr1q21.2. In B cells, we identified a CE mark at the prox-
imal promoter of HIST4H4 (Additional file 1: Table S1).
Given that 60% of CIITA BIs identified outside of the
MHC were not overlapping RFX5 BI, we sought to fur-
ther characterise CIITA recruitment and possible associ-
ated co-factors. We first investigated the occurrence of
the tri-motif CIITA module comprised of RFX5, CREB
and NF-Y [20] within 150 bp of sequence around peak
summits for CIITA BIs localised to within 10 kb up-
stream of a TSS. The module was most prevalent for
CIITA BIs localised at known CIITA targets that include
genes within the MHC Class II region (Figure 2D and
Additional file 1: Table S1). The module was also enriched
within the novel CIITA BIs identified in this study but
significantly less than observed for CIITA BI involving
known loci.We then investigated occurrence of known DNA bind-
ing motifs for other transcription factors where CIITA
recruitment was occurring in the absence of RFX5 bind-
ing. We analysed the 150 bp sequences spanning CIITA
peak summits for enriched consensus sequences using
the MEME-ChIP suite [21,22]. This showed significant
enrichment of several consensus motifs notably STAT3
and SPI1 in IFN-treated monocytes (Additional file 1:
Table S1).
To further investigate this, we analysed upstream regu-
lators of genes associated with CIITA BIs not overlap-
ping RFX5 BI using IPA (Additional file 1: Table S1).
Analysis of all genes associated with CIITA BIs revealed
that while CE marks were most significantly associated
with RFX5 (P = 4.5 × 10-10) and NLRC5 (P = 1.4 × 10-8),
CIITA BI not overlapping RFX5 were significantly en-
riched for transcription factors STAT1 (P = 2.2 × 10-7),
JUN (P = 8.7 × 10-7), MYC (P = 8.9 × 10-7), STAT3
(P = 5.4 × 10-6) and NFkB complex (7.5 × 10-6). A similar
pattern was seen when genes associated with CIITA BI in
the MHC were compared with non-MHC genes. Consid-
ering specific cell types, this effect was most clearly seen
on analysis of induced monocytes (Additional file 1:
Table S1) with STAT1 (P = 2.3 × 10-8), NFkB complex
(P = 2.8 × 10-7) and STAT3 (P = 3.8 × 10-7) the most sig-
nificantly enriched transcriptional regulators in CIITA BI
not overlapping RFX5.
The motif analysis and upstream regulator data raise the
hypothesis that members of the STAT family may be in-
volved in CIITA recruitment in the absence of RFX5 but
further work is required to test this. In terms of diseases
and functions, the overall gene set we identified as associ-
ated with CIITA BIs not overlapping RFX5 was most sig-
nificantly enriched for infectious disease (viral infection)
(P = 1.6 × 10-8) followed by a variety of autoimmune dis-
eases with effects most clearly seen in treated monocytes.
In B cells and naïve monocytes enrichment for cancer phe-
notypes was noted, with death receptor signalling identified
on pathway analysis in B cells (Additional file 1: Table S1).
Insights from the genetical genomics of CIITA
Mapping gene expression as a quantitative trait has the
potential to define master regulatory networks through
resolution of trans associations in which differential gene
expression for a gene set are seen to be associated with a
specific genetic marker [23]. We have reported genome-
wide expression quantitative trait (eQTL) analysis in dif-
ferent primary human cell populations [24]. This global
analysis included evidence of a local, cis-eQTL involving
CIITA that was specific to B cells. Given the role of
CIITA as a master regulator we sought to further resolve
this association and to investigate whether there was evi-
dence of associated trans-eQTL networks that could in-
form CIITA function and modulated genes.
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principal components of the expression data as covari-
ates [25] to further define association within 1 Mb of
CIITA for the 281 healthy volunteers using a genome-
wide panel of 651,210 SNP markers [24]. This resolved that
the strongest association involved a single nucleotide poly-
morphism (SNP) rs11074938 in the 13th intron of CIITA
(P = 6.9 × 10-20, FDR = 3.2 × 10-15) (Figure 5A to C). Ana-
lysis of trans associations involving this SNP (Figure 5D)
revealed multiple associations with MHC Class II genes,
notably HLA-DMA, HLA-DOA and HLA-DRA consistent
with the known role of CIITA in regulation of these genes.
Non-MHC trans associations included genes that are
known to show evidence of CIITA recruitment such as
RFX5 and TPP1 while for others including OLFML2A
and PARVG we find ChIP-seq mapping supports a role
for CIITA.
We sought to determine whether the trans association
with transcript expression seen for rs11074938 with
MHC Class II genes was also observed at the protein
level. We assayed MHC class II surface expression on B
cells in whole blood from healthy volunteers by multi-
parametric flow cytometry and observed that individuals
possessing one or two copies of the rs11074938 A allele
compared to the G allele expressed higher levels of pro-
tein (Figure 5E).
A cis-eQTL for CIITA involving allele-specific recruitment
of NF-KB
In light of the cis and trans associations for rs11074938
in B cells, we sought to investigate the functional basis
for this. We first studied the regulatory functional gen-
omic landscape of the sequence variant. Analysis of
publically available ENCODE data revealed that SNP
rs11074938 was located within a DHS in human primary
B cells and lymphoblastoid cell lines (LCLs) but not
monocytes (Figure 6A). The position in a region of open
chromatin was consistent with the hypothesis that the
variant is located in a regulatory element. This was fur-
ther supported by the presence of specific histone marks
including H3K4Me1 and evidence that this is a phylo-
genically conserved region (vertebrate conserved elem-
ent, LOD score 31).
Analysis of ChIP-seq data [26] revealed that the SNP
was located within an NF-KB target site in LCLs
(Figure 6A) and contained an NF-KB consensus binding
motif. We investigated whether the A to G substitution
could modulate predicted binding affinity using a publi-
cally available database identifying binding sites of NF-
KB by a combination of protein-binding microarrays and
surface plasmon resonance [27]. The ancestral A allele
was predicted to show higher binding affinity for NFKB1/
RELA (z-score human 3.25 with A allele vs. 2.83 with G
allele) and NFKB2/RELB (z-score 3.16 A vs. <2 G) butthe situation is complex with the G allele also predicted
to show higher affinity for the NFKB2 homodimer (z-score
4.38 G vs. 3.86 A).
To investigate this further we characterised NF-KB bind-
ing by electrophoretic mobility shift assay (EMSA). EMSA
using recombinant NFKB1 and RELA proteins demon-
strated that with the NFKB1/RELA heterodimer there was
greater binding to the A allele compared to the G allele
(Figure 6B). Weak binding was observed for NFKB1 alone
with no evidence of RELA binding as a homodimer.
We then proceeded to determine whether allelic differ-
ences in NF-KB binding were present ex vivo using
ChIP-seq data for a panel of five LCLs heterozygous for
rs11074938 [26]. This revealed that there was signifi-
cantly more RELA binding to the A allele compared to
the G, with on average 66.1% (SD 8.1) of reads mapping
to the A allele (P =0.008) (Figure 6C).
In order to investigate whether the intronic sequence
spanning the SNP rs11074938 had regulatory activity
that could be modulated in an allele-specific manner, we
cloned the region into a reporter gene construct. Given
the low transient transfection efficiency of human B cell
lines, we performed reporter gene assays in a lympho-
blast cell line of T cell origin (Jurkat). This demonstrated
evidence of increased enhancer activity for the A versus
the G allele of rs11074938 with allele-specific differences
in protein-DNA interactions also seen in this cell line
(Additional file 2: Figure S10).
Discussion
This work defines a high-resolution map of CIITA occu-
pancy within the MHC and genome-wide, presenting
evidence for complexity and specificity in the associated
enhanceosome complex across different primary periph-
eral blood cell types and conditions. The results support
a role for CIITA beyond the MHC that is often not asso-
ciated with RFX5 binding but occurs in proximity to
genes enriched for immune function and infectious dis-
ease, and highlights diverse potential roles including re-
cruitment at histone gene clusters.
The biology of CIITA regulation for MHC class II genes
is well established [2,7,8]. Our data support evidence for
distal as well as classical proximal sites of CIITA recruit-
ment [9], including novel BIs which, as elsewhere in the
class II region, appear highly stereotyped in terms of
enhanceosome composition and partner DNA binding
proteins notably RFX5. Similarly, for the class I region the
observed binding is consistent with previous findings at
classical genes while supporting evidence for binding sites
proximal to TRIM26 and PPP1R10 [10,28].
Genome-wide, the picture is more complex with
60% of observed CIITA BIs not associated with RFX5
binding based on ChIP-seq performed on the same
input chromatin. As seen in the MHC, occupancy was
Figure 5 Local and distant eQTL associations for eSNP rs11074938 involving CIITA. (A) Manhattan plot showing association on chromosome
16p13. (B) Regional association plot for CIITA demonstrating peak association for rs11074938 located in intron 13 of CIITA. (C) Box-plot showing allelic
association of rs11074938 with levels of CIITA expression across 281 individuals. (D) Circular plot illustrating genomic location of eQTLs for rs11074938
in B cells. From outside to inside: chromosome number; relative distance along chromosome; coloured dots are cis and trans-eQTLs (size relative -log10
P value as per legend); the outer grey dot is a cis-eQTL for CIITA while inner blue dots are trans-eQTLs; lines indicate genes regulated in trans rendering
these as potential CIITA targets, only eQTL mapping to genes with P <3 × 10-4 in the dataset (n = 281) have been shown. (E) Association of rs11074938
with levels of pan MHC class II protein across 37 individuals quantified using multi-parametric flow cytometry. Difference in measured protein levels
between homozygous individuals with the A allele as compared to the G allele was significant (*denotes Kruskall-Wallis P = 0.02; MFI = Median
fluorescence intensity; data shown have been normalised to control isotype staining).
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Figure 6 Functional characterisation of CIITA regulatory variant. (A) Genomic landscape of CIITA and the eSNP rs11074938. Data from
ENCODE project for a lymphoblastoid cell line, GM12878 and primary CD20+ B cells and CD14+ monocytes. The SNP, rs11074938 is localised to a
DHS specific to B cells that is further coincident with a NF-KB ChIP-seq peak. (B) EMSA demonstrating allele-specific binding for NF-KB involving
rs11074938. Recombinant NF-KB proteins NFKB1 (lanes 1 and 4), RELA (lanes 2 and 5) or both (lanes 3 and 6) incubated with probes corresponding
to the two different alleles for rs11074938, either A (lanes 1 to 3) or G (lanes 4 to 6). (C) Ratio of A and G alleles within sequenced reads spanning
SNP rs11074938 from NF-KB ChIP-seq analyses of five heterozygous individuals.
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tin and was predominantly within 2 kb of a gene. The data
confirmed some previously identified non-MHC genes
such as CD74 and B2M [8,11,19] but also highlighted
many additional loci notably after monocytes were treated
with IFNγ in which hundreds of additional BIs were
revealed compared to the naïve state consistent with previ-
ous observations that CIITA-mediated regulation is intim-
ately linked to treatment with interferons [2]. Examples of
genes associated with CIITA BIs include key mediators
such as STAT1 and STAT3, observed specifically in mono-
cytes treated with IFNγ and B cells, respectively, as well as
regions of enrichment for CIITA BIs such as identified
within the major histone gene clusters at chromosomes
6p21 and 1q21.
It has been proposed that in addition to its well-
defined enhanceosome function in the MHC, CIITAmay function to modulate transcription of a target gene
through an alternative mode of action involving forma-
tion of a TFIID-like complex in conjunction with part-
ners TAF6, TAF9 and TBP [19]. Within this complex, a
TATA-box binding protein (TBP) is proposed to bind
DNA and through the involvement of other chromatin
modifying enzymes that bring about re-modelling of
localised regions within the chromatin, CIITA within
this TFIID-like complex may subsequently further dimerise
with CIITA in a canonical RFX5-containing enhanceo-
some. The entire mechanism is however, currently not well
understood.
We find that the well characterised, tri-motif CIITA
module (RFX5, CREB and NF-Y) was less prevalent
within novel CIITA BIs we identified but occurred more
frequently than in a control set. Our analysis of peak sum-
mits within CIITA BIs not overlapping RFX5 highlighted
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while STAT1 and STAT3 were significant predicted up-
stream transcriptional regulators for gene sets associated
with such CIITA BIs. These data suggest a possible role for
STAT family transcription factors in the recruitment of
CIITA outside the MHC but further work is required to
characterise this.
This work has highlighted the potential informative-
ness of integrating genomic profiling approaches such as
ChIP-seq with trans-eQTL mapping to define modulated
gene networks. We identified a strong local association
with CIITA expression that we resolved to a specific cis
acting expression-associated SNP (eSNP) involving allele-
specific recruitment of NF-KB at an intronic regulatory
element and differential gene expression. Further work is
required to determine the detailed allele-specific transcrip-
tional mechanisms involved in this cis-association. Strik-
ingly, we find this eSNP was associated in trans with a
gene network that included classical class II genes demon-
strated at the transcript level and subsequently validated at
the protein level. Moreover, the trans network also in-
cluded non-MHC genes, both known targets such as RFX5
and TPP1, and novel genes where we also find evidence of
CIITA BIs by ChIP-seq. Our study had limitations in terms
of sample size for determining a more extensive modulated
gene network and further analysis at different time points
following activation and CIITA expression are likely to be
required for in-depth profiling and complete integration
with maps of CIITA occupancy, together with functional
evidence linking recruitment with differences in gene regu-
lation. However the data illustrate that an integrated ap-
proach may be highly informative.
Conclusions
Our study has demonstrated that CIITA recruitment com-
monly occurs outside the MHC, often not in the setting of
a classical enhanceosome with RFX5, and involves genes
enriched for immune function and infectious disease. We
have functionally characterised a local regulatory variant of
CIITA acting through allele-specific recruitment of NFkB
which modulates MHC and non-MHC CIITA target genes
in trans. The work provides a route-map for further studies
to understand the role of CIITA in gene regulation
genome-wide, defining complexity and cell type specificity
as well as the potential utility of combining analysis of BIs
through approaches such as ChIP-seq with experiments of
a nature whereby gene networks may be identified through
common variants modulating gene expression locally and
at a distance through master regulators.
Materials and methods
Nuclear extracts, electrophoretic mobility shift assays (EMSA)
Recombinant NFKB1 (#31101) and RELA (#31102) pro-
teins were obtained from Active Motif, UK. Nuclearextracts were prepared from Jurkat cells as previously
described [29]. Oligonucleotide probes were radiolabelled
with 32P-dCTP (Perkin Elmer, Beaconsfield, UK) and
EMSA performed as previously described [30]. Probes
were generated by annealing forward and reverse oli-






The study was approved by the Oxfordshire Research
Ethics Committee (COREC reference 06/Q1605/55) and
volunteers of European ancestry were recruited in the
Oxfordshire area following written informed consent
through NIHR Oxford BioBank.
Flow cytometry for analysis of HLA Class II expression
We assayed HLA class II expression by multi-parametric
flow cytometry for whole blood from 37 healthy volunteers
using a three-step procedure adapted from a protocol
kindly shared by R. Apps from the National Cancer
Institute [31]. Human IgG (Sigma-Aldrich, Dorset, UK)
was added to each tube, followed by mouse anti-human
antibodies directed against all class II alleles (clone Tu39
and SK10/SPV-L3 combined) or an isotype control
(murine IgG, Sigma-Aldrich). After 20 min, cells were
washed with Dulbecco’s phosphate buffered saline (DPBS,
Sigma-Aldrich) and sheep IgG was added to each tube
followed by sheep-anti-mouse PE (Sigma-Aldrich). After a
further 20-min incubation at 4°C, cells were washed, sec-
ondary antibody sites were blocked with mouse IgG
(Sigma-Aldrich) and mouse-anti-human CD19-FITC (clone
J3-119, Beckman Coulter) was added. This suspension was
incubated for 20 min at 4°C, cells were subsequently
washed and red blood cells lysed with VersaLyse (Beckman
Coulter, High Wycombe, UK) over 20 min, then washed
and fixed with Reagent A (Life Technologies, Paisley, UK).
Data were acquired immediately on a single FACSCanto
(BD) machine using standardized settings verified for each
data collection batch using BD seven-colour setup beads
(BD). A minimum of 10,000 gated B cells were acquired for
each sample (gating strategy illustrated in Additional file 2:
Figure S11). The genotype of samples was anonymised dur-
ing flow cytometry. Fluorescence-minus-one controls were
used to set gate thresholds. Data were analysed in FLowJo
(v10.0.6) and Graphpad Prism (v6). Data were normalised
for isotype staining by simple subtraction of the isotype
MFI in the PE channel from the HLA-II signal.
Isolation of primary immune cells and ChIP-seq
Leukocyte cones derived from different anonymous indi-
viduals were obtained from the NHS Blood and Transplant
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as described by Neron and co-workers [32]. Briefly, a
Ficoll gradient coupled with successive washes were
used to isolate PBMCs from the cones [24]. Automated
magnetic activating cell sorting, or autoMACS method
(Miltenyi) was used to positively separate CD14+ and
CD19+ cell populations starting from 500 million
PBMCs following manufacturer’s instructions [33]. The
technique routinely yields cell purity levels greater than
90% when cross-validated using a FACS-based assay.
CD19+ cells were cross-linked for 10 min in 1% formal-
dehyde, while CD14+ cells were treated with 10 ng/mL
IFNγ (R&D Systems) for 24 h alongside an untreated
control before cross-linkage. Chromatin isolation, sonic-
ation using a BioRuptor (Diagenode) and immunoprecip-
itation using CIITA (Diagenode) and RFX5 (Santa Cruz)
ChIP-grade antibodies were performed. Quality control
of ChIP-ped DNA was achieved by quantification on a
Qubit 2.0 fluorometer (Invitrogen) using the Quant-iT
dsDNA HS Assay Kit (Invitrogen). In addition, real-time
quantitative PCR was employed to determine enrich-
ment at various genomic locations prior to sequencing
(Additional file 2: Supplemental Methods). Approximately
5 to 10 ng of ChIP-ped DNA from each sample was proc-
essed into libraries, amplified and sequenced using 51-bp
paired-end runs on the Illumina HiSeq (Additional file 2:
Supplemental Methods).
ChIP-ddPCR enrichment
Validation ChIP experiments with two CIITA antibodies
(Diagenode C15410062 and SantaCruz sc-48797X) were
performed using B cells and monocytes derived from an
independent leukocyte cone. ddPCR was carried out on
the QX-100 PCR system (Bio-Rad), using labelled probes
and primer sets (sequences listed in Additional file 2:
Supplementary Methods) obtained from MetaBion GmbH
and following manufacturer’s procedures for ddPCR
Supermix for Probes (Bio-Rad 186-3010). A duplexed con-
figuration was employed with each well containing an
assay for the sample (labelled in FAM) and a second assay
for the Rab4A-control region (labelled in YakimaYellow).
Enrichment of ChIP over input was determined after nor-
malising for the ratio of corresponding measurements for
the control region, Rab4A.
Bioinformatic and statistical analysis including eQTL
mapping, peak calling and derivation of BIs
Stampy version 1.0.21 [34] was employed to align 51 bp-
reads to the Human genome UCSC hg19 (GRCh37) using
the PGF haplotype as our reference for the MHC region.
Processing and filtering of mapped reads were done using
Bamtools version 2.3.0 and Samtools version 0.1.17 to re-
move duplicates, singletons and improperly mapped read
pairs that included mappings to non-unique locations anddiscordant locations. Additionally, read pairs were re-
moved when one or both reads had low mapping
quality (<20). Across samples, 38% to 83% of read pairs
remained after this filtering (Additional file 1: Table S1).
Enriched peaks were determined with ‘Model-based ana-
lysis of ChIP’ (MACS version 2.0.10) by comparing ChIP
samples to input samples with FDR <5%. Bedtools version
2.3.0 was used to identify regions shared across the 12
samples. Contiguous, shared regions were merged into a
BI when there were enriched peaks for CIITA or RFX5
in both individuals within a single cell type/condition
(Additional file 2: Figure S12). This generated 1,010 BIs
representative of CIITA and RFX5 binding for further ana-
lysis. Plots generated based on BigWig representations of
ChIP-seq data in the UCSC Browser show on the y-axis
enrichment of peaks (ChIP versus input) with peak-
enrichment values normalised using the SPMR (signal per
million reads) function.
Analysis of known CIITA module (RFX5, CREB and NF-Y)
within CIITA BIs
Three distinct groupings of 150 bp sequence segments
around peak summits were analysed: (1) two groups
comprised of segments within CIITA BIs that are local-
ised to within 10 kb upstream or 150 bp downstream of
a TSS and that are either known CIITA targets (20 genes)
or novel targets identified in this study (275 genes); (2) a
control set comprised of 1,000 genes randomly selected
from the genome with sequence extracted 10 kb 5′ and
150 bp 3′ of the TSS from which 150 bp segments ran-
domly selected. The tool Biostrings 2.32.1 from the
BioConductor Package was used to scan for presence
of RFX5, CREB and NF-Y motifs (source for PWM-
Position Weight Matrices used: JASPAR [35], Transfac
[36] and Human Protein-DNA Interactome (hPDI) [37])
and score similarity of any motif identified within a seg-
ment against the PWM in question. This was carried out
iteratively within a segment to obtain a CIITA module
with motifs identified in the correct order and with the
best score (highest similarity to PWM for all components).
An average of scores for the components was computed
and this is used as a measure of the prevalence of this
known CIITA module within a CIITA BI.
Motif search
Peak summits in BIs were used to identify enriched con-
sensus sequences with known DNA-binding motifs using
MEME-ChIP suite. The peak summits for each sam-
ple were extended to 75 bp-length sequences into
both directions. Equivalent sized DHS in primary cells
(ENCODE) were used for background estimation. A cus-
tomised database containing 569 motifs was created
using information from the JASPER and hPDI repositor-
ies. We estimated a new Markov model for background
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less than 1.0 (default option) and P value of less than 0.01
to the known motifs were used for further study. To get
motifs similar to known motifs, we searched ‘tomtom.txt’
output files for each sample and selected motifs occurring
in both individuals in the same condition.
Determining biological themes from genes that are
regulated by CIITA
We annotated BIs within 10 kb from the TSS of the
nearest gene using ChIPpeakAnno [38] and CisGenome
[39]. Gene clusters formed using CIITA BIs from B cells,
naïve and treated monocytes were analysed through the
use of the DAVID Bioformatics Suite and Ingenuity
Pathway Analysis (IPA, Ingenuity Systems [40]). IPA was
used to define gene networks, significant upstream regu-
lators and relationships with canonical signalling pathways.
Enrichment of differentially expressed genes within
CE-marks and CIITA BIs
To investigate whether genes associated with CIITA BIs in
treated monocytes are enriched for genes that are differen-
tially expressed when compared to naïve monocytes we
used our published gene expression data [16]. Differential
gene expression analysis was performed using the limma
package. All genes with expression data were ranked by
differential expression (P values). We then considered the
distribution of ranks within two different sets of genes;
genes associated with a CE mark and genes associated
with CIITA BIs without RFX5. We also examined genes
associated with CIITA BIs (includes CE marks and CIITA
BIs without RFX5) that are either known CIITA targets
(Additional file 1: Table S1) or novel targets identified in
this study.
Data access
ChIP-seq datasets have been deposited into the Array-
Express database [41] under accession number E-MTAB-
2424.
Additional files
Additional file 1: Table S1. Worksheets S1.1-1.22.
Additional file 2: Supplemental Methods and Figures S1-12.
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